SCHEMBL3248232

SCHEMBL3248232

CN(C)S(=O)(=O)c1ccc2[nH]c(=O)c3[nH]cc(C(=O)O)c3c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.47
HPGD P15428 3/20 0.47
KDM4E B2RXH2 7/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ADRB2 P07550 1/20 0.45
RECQL P46063 1/20 0.45
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
MAPT P10636 2/20 0.43
AKR1B1 P15121 1/20 0.41
GAA P10253 2/20 0.40
CYP2C19 P33261 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
ALDH1A1 P00352 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
USP2 O75604 1/20 0.39
POLB P06746 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTR6 P50406 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3250548 0.88 HPGD (0.56) HSD17B10HPGDKDM4EMEN1KMT2A
SCHEMBL3248331 0.88 KDM4E (0.60) HSD17B10HPGDKDM4EMEN1KMT2A
SCHEMBL3250948 0.87 KDM4E (0.46) HSD17B10HPGDKDM4EMEN1KMT2A
SCHEMBL3250056 0.87 GAA (0.47) HSD17B10HPGDKDM4EMEN1KMT2A
SCHEMBL3241909 0.87 KDM4E (0.50) HSD17B10HPGDKDM4EMEN1KMT2A
SCHEMBL3249438 0.86 PTPN11 (0.45) HSD17B10HPGDKDM4EMEN1KMT2A
SCHEMBL3250315 0.86 KDM4E (0.46) HSD17B10HPGDKDM4EMEN1KMT2A
SCHEMBL3251841 0.86 MAPT (0.51) HSD17B10HPGDKDM4EMEN1KMT2A
SCHEMBL3245348 0.86 HSD17B10 (0.69) HSD17B10HPGDKDM4EMEN1KMT2A
SCHEMBL3245166 0.86 KDM4E (0.44) HSD17B10HPGDKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
EP-1899335-A1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2008-03-19 EP claimed
WO-2007003611-A1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2007-01-11 WO claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed
EP-1899335-A1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2008-03-19 EP disclosed
WO-2007003611-A1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PIERRE FABRE MEDICAMENT (FR) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 HSD17B10 3847/4885HPGD 882/4885KDM4E 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.